Changes

{{Under Construction}}

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)]].

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)]].

}}</blockquote>

}}</blockquote>

==Primary Author(s)*==

==Primary Author(s)*==

__TOC__

__TOC__

==Cancer Category/Type==

==Cancer Category / Type==

[[Mature B cell neoplasm]]

[[Mature B cell neoplasm]]

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":2">{{Cite journal|last=Troppan|first=Katharina|last2=Wenzl|first2=Kerstin|last3=Neumeister|first3=Peter|last4=Deutsch|first4=Alexander|date=2015|title=Molecular Pathogenesis of MALT Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/25922601|journal=Gastroenterology Research and Practice|volume=2015|pages=102656|doi=10.1155/2015/102656|issn=1687-6121|pmc=4397421|pmid=25922601}}</ref></blockquote>

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":2">{{Cite journal|last=Troppan|first=Katharina|last2=Wenzl|first2=Kerstin|last3=Neumeister|first3=Peter|last4=Deutsch|first4=Alexander|date=2015|title=Molecular Pathogenesis of MALT Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/25922601|journal=Gastroenterology Research and Practice|volume=2015|pages=102656|doi=10.1155/2015/102656|issn=1687-6121|pmc=4397421|pmid=25922601}}</ref></blockquote>

</blockquote>

</blockquote>

==Individual Region Genomic Gain/Loss/LOH==

==Individual Region Genomic Gain / Loss / LOH==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

|}

|}

<blockquote class='blockedit'>{{Box-round|title=v4:Individual Region Genomic Gain/Loss/LOH|The content below was from the previous version of the page. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Individual Region Genomic Gain / Loss / LOH|The content below was from the previous version of the page. Please incorporate above.}}

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

|}

|}

==Gene Mutations (SNV/INDEL)==

==Gene Mutations (SNV / INDEL)==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the previous version of the page. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV / INDEL)|The content below was from the previous version of the page. Please incorporate above.}}

<nowiki>*</nowiki>''Citation of this Page'': “Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue</nowiki>.[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases E]]

<nowiki>*</nowiki>''Citation of this Page'': “Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue</nowiki>.

[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases E]]